Bladder Preservation for muscle invasive disease. Nicholas
|
|
- Alexandrina Gray
- 5 years ago
- Views:
Transcription
1 Bladder Preservation for muscle invasive disease Nicholas 1
2 Overview Evidence base for bladder preservation as alternative to surgery Chemoradiotherapy compared to radiotherapy alone
3 Age-standardised 5-year survival for bladder cancer N Europe Ireland and UK Central Europe Southern Europe Eastern Europe Europe Rafael Marcos-Gragera, et al Urinary tract cancer survival in Europe : Results of the population-based study EUROCARE-5 European Journal of Cancer, Volume 51, Issue 15, 2015,
4 Background Bladder cancer outcomes have not significantly improved for 30 years Zehnder P, Studer UE, Skinner EC, Thalmann GN, Miranda G, Roth B, Cai J, Birkhauser FD, Mitra AP, Burkhard FC, Dorin RP, Daneshmand S, Skinner DG, Gill IS. Unaltered oncological outcomes of radical cystectomy with extended lymphadenectomy over three decades. BJU Int 2013;112:E51-8 Presented by: Nick James
5 Background Bladder cancer outcomes have not significantly improved for 30 years Zehnder P, Studer UE, Skinner EC, Thalmann GN, Miranda G, Roth B, Cai J, Birkhauser FD, Mitra AP, Burkhard FC, Dorin RP, Daneshmand S, Skinner DG, Gill IS. Unaltered oncological outcomes of radical cystectomy with extended lymphadenectomy over three decades. BJU Int 2013;112:E51-8 Presented by: Nick James
6 IS SURVIVAL BETTER AFTER SURGERY?
7 Survival from UK Registry data 453 UK pts, Ratio RT:cystectomy 3:1 10 year survival RT 22% Surgery 24% Munro NP, Sundaram SK, Weston PM, et al. A 10-year retrospective review of a nonrandomized cohort of 458 patients undergoing radical radiotherapy or cystectomy in Yorkshire, UK. Int J Radiat Oncol Biol Phys 2010;77:
8 Canadian Registry Data Bladder Cancer Variations in the use of total cystectomy and in the use of pelvic RT among the regions of Ontario were not associated with variations in survival. Survival was correlated with tumour related parameters Hayter CR, Paszat LF, Groome PA, et al: The management and outcome of bladder carcinoma in Ontario, Cancer 89: , 2000
9 WHAT CAN WE LEARN FROM OTHER CANCERS?
10 Anal cancer Primary therapy was surgery up until mid- 1980s Various chemo-rt regimens showed high activity with range of agents including 5FU, MMC, cisplatinum during 1970s surgery as the primary therapeutic modality has been abandoned. Anal cancer: ESMO-ESSO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up Ann Oncol (2014) 25 (suppl 3):iii10- iii20.doi: /annonc/mdu159
11 CAN WE SALVAGE LOCAL FAILURES?
12 Primary vs Salvage Cystectomy Addla et al. The Journal of Urology Vol. 181, Issue 4, Supplement, Page 633
13 Are complication rates higher with salvage cystectomy? 426 primary and 420 salvage cystectomies Single institution Differential Complication Rates Following Radical Cystectomy in the Irradiated and Nonirradiated Pelvis Vijay A.C. Ramani, Satish B. Maddineni, Ben R. Grey, Noel W. Clarke. Eur Urol 57 (2010)
14 Are complication rates higher with salvage cystectomy? Differential Complication Rates Following Radical Cystectomy in the Irradiated and Nonirradiated Pelvis Vijay A.C. Ramani, Satish B. Maddineni, Ben R. Grey, Noel W. Clarke. Eur Urol 57 (2010)
15 Are complication rates higher with salvage cystectomy? This large series from a high-volume centre demonstrates no difference in perioperative mortality in primary or postradiation salvage radical cystectomy. Similarly, there was no significant difference in the incidence of most of the surgical or medical complications.. Differential Complication Rates Following Radical Cystectomy in the Irradiated and Nonirradiated Pelvis Vijay A.C. Ramani, Satish B. Maddineni, Ben R. Grey, Noel W. Clarke. Eur Urol 57 (2010)
16 Age at diagnosis Median age in BC2001 and BCON Median age in USC series Median age in BA06 & SWOG 8710 Male cases Female cases
17 Choice of treatment Surgery and radiotherapy data relate to different segments of the population Hence age/fitness is important factor in treatment decisions
18 CHEMORADIATION VS RADIOTHERAPY ALONE
19 Synchronous Chemoradiotherapy Numerous phase I/II studies showing feasibility and safety Three phase III studies RT vs RT + Cisplatinum (NCIC) RT vs RT + nicotinamide/carbogen (BCON) RT vs RT + 5FU/MMC (BC2001)
20 Synchronous Chemoradiotherapy Numerous phase I/II studies showing feasibility and safety Three phase III studies RT vs RT + Cisplatinum (NCIC) RT vs RT + nicotinamide/carbogen (BCON) RT vs RT + 5FU/MMC (BC2001)
21 Cisplatinum and RT +/- surgery Coppin CM, Gospodarowicz MK, James K, et al. Improved local control of invasive bladder cancer by concurrent cisplatin and preoperative or definitive radiation. Journal of Clinical Oncology 1996;14:2901-7
22 100 BCON Results Carbogen + Nicotinamide Relapse-free survival (%) HR 0.86 ( ) p=0.06 at 3 years LogŠrank p = 0.06 RT + CON RT alone Time from randomization (months) Control arm HR 0.85 ( ) p=0.04 Relapse free survival Overall survival Hoskin PJ, Rojas AM, Bentzen SM, et al: Radiotherapy with concurrent carbogen and nicotinamide in bladder carcinoma. J Clin Oncol 28:4912-8, 2010
23 BC2001: Trial design Patients with muscle invasive bladder cancer RANDOMISE CT No CT Standard volume RT + synchronous chemotherapy Standard volume RT Reduced high dose volume RT + synchronous chemotherapy Reduced high dose volume RT srt RHDV RT Pragmatic design: Centres could offer double or either single randomisation
24 RTOG 6 month toxicity outcomes Chemo RT RT only Grade 0 Grade 1 Grade 2 Grade 3 Grade 4 Unknown n= 291, 145 RT only, 146 chemo-radiotherapy
25 Loco-regional disease free survival in chemotherapy randomisation Proportion locoregional disease-free HR (95% CI) = 0.68 ( ) Stratified logrank p= Months since randomization N at risk (events) Chemo-RT 182 (35) 108 (14) 76 (3) 66 (1) 56 (1) 46 (1) 25 RT 178 (54) 96 (16) 69 (4) 58 (1) 44 (0) 35 (1) 18 Loco-regional control (invasive and non-invasive) Proportion invasive locoregional disease-free HR (95% CI) = 0.57 ( ) Stratified logrank p= Months since randomization N at risk (events) Chemo-RT 182 (20) 121 (7) 93 (3) 79 (0) 66 (0) 54 (1) 32 RT 178 (37) 109 (11) 85 (2) 74 (2) 52 (0) 39 (0) 20 Invasive loco-regional control James et al, Radiotherapy with or without chemotherapy for invasive bladder cancer. NEJM ,
26 Patterns of recurrence after chemort Any recurrence 93/182 pts Loco-regional recurrence 53 Distant recurrence or second primary 40 Non-muscle invasive 25 Muscle invasive 18 Pelvic nodes 6 Metastasis 29 Second primary 11
27 10 YEAR OUTCOMES BC2001
28 Updated results - CT comparison Loco-Regional Control (LRC) Invasive Loco-Regional Control HR (95% CI) = 0.61 ( ) Stratified logrank p=0.004 Adjusted HR (95%CI): 0.59 ( ), p=0.003 CT No CT Months since randomisation N at risk (events) CT 182 (48) 77 (4) 65 (2) 54 (0) 28 (1) 8 (0) No CT 178 (71) 72 (5) 53 (5) 38 (2) 28 (1) 13 (0) Invasive Loco-Regional Control (ILRC) HR (95% CI) = 0.55 ( ) Stratified logrank p=0.006 Adjusted HR (95%CI): 0.52 ( ), p=0.004 CT No CT Months since randomisation N at risk (events) CT 182 (27) 94 (3) 77 (1) 66 (1) 37 (1) 13 (0) No CT 178 (50) 88 (4) 63 (1) 51 (2) 37 (1) 15 (0) Snapshot of data: July 2016, N=360, Median FUP m
29 Study ID Study Study Study LRDFS - consistency across subgroups ID rtrand1 rtrand1 rtrand1 rtrand1 rtrand2 rtrand2 rtrand2 rtrand2 rtrand3 rtrand3 rtrand3 rtrand3 ptds1 ptds2 ID ID Randomised srt Randomised RHDV 58 Elect srt 239 ptds1 ptds1 ptds1 RT dose 55Gy/20F ptds2 ptds2 ptds2 RT dose 64Gy/32F 217 neoadj1 neoadj1 neoadj1 neoadj1 Neoadjuvant CT No neoadjuvant CT 242 neoadj2 neoadj2 neoadj2 neoadj2 Primary Primary Primary Primary Primary analysis 360 HR (95% HR CI) (95% HR (95% CI) HR (95% CI) CI) N P-value Hazard ratio (95% CI) 0.79 (0.36, ) 0.79 (0.36, (0.36, ) (0.36, 1.77) (0.37, ) 1.01 (0.37, (0.37, ) (0.37, 2.77) (0.38, ) 0.59 (0.38, (0.38, ) (0.38, 0.91) (0.41, ) 0.75 (0.41, (0.41, ) (0.41, 1.37) (0.40, ) 0.63 (0.40, (0.40, ) (0.40, 0.97) (0.32, ) 0.58 (0.32, (0.32, ) (0.32, 1.08) (0.47, ) 0.72 (0.47, (0.47, ) (0.47, 1.12) (0.47, ) 0.67 (0.47, (0.47, ) (0.47, 0.95) Favours Favours CT Favours CT Favours CT Favours no CT CT Favours no Favours CT no CT no CT
30 Updated results - CT comparison Overall Survival Bladder Cancer Specific survival HR (95% CI) = 0.88 ( ) Stratified logrank p= 0.31 Adjusted HR (95%CI): 0.81 ( ), p=0.100 CT No CT Months since randomisation N at risk (events) CT 182 (69) 111 (20) 88 (5) 80 (12) 59 (11) 25 (6) No CT 178 (69) 107 (33) 73 (14) 58 (5) 47 (5) 18 (1) Bladder Cancer specific Survival HR (95% CI) = 0.79 ( ) Stratified logrank p= 0.11 Adjusted HR (95%CI): 0.73 ( ), p=0.043 CT No CT Months since randomisation N at risk (events) CT 182 (55) 111 (15) 88 (3) 80 (4) 59 (2) 25 (3) No CT 178 (60) 107 (25) 73 (9) 58 (3) 47 (0) 18 (1) Snapshot of data: July 2016, N=360, Median FUP m
31 Updated results - CT comparison Metastasis Free Survival Cystectomy Incidence HR (95% CI) = 0.78 ( ) Stratified logrank p= 0.09 Adjusted HR (95%CI): 0.74 ( ), p=0.051 CT No CT Months since randomisation N at risk (events) CT 182 (61) 101 (10) 82 (2) 71 (3) 42 (2) 15 (2) No CT 178 (71) 95 (18) 67 (6) 53 (2) 39 (0) 17 (1) Salvage Cystectomy Rate HR (95% CI) = 0.54 ( ) Stratified logrank p= year rate: CT 11% (7-17) No CT 17% (12-24) CT No CT Months since randomisation N at risk (events) CT 182 (15) 98 (3) 79 (1) 71 (1) 51 (0) 20 (0) No CT 178 (25) 95 (3) 64 (4) 49 (1) 41 (0) 18 (0) Snapshot of data: July 2016, N=360, Median FUP m
32 Proportion of invasive loco-regional control Proportion of invasive loco-regional control Effect of Multivariate factors on ILRC No neoadjuvant CT 3-yr ILRC: Neoadjuvant CT 90.1% RT+CT 83.0% 82.9% No Res mass RT+CT RT No Res 71.4% 72.5% mass RT RT+CT Neoadjuvant chemotherapy and synchronous Residual 56.2% 56.0% mass RT+CT RT 35.3% Residual mass RT 3-yr ILRC: chemotherapy do different things Months since randomisation Months since randomisation 32
33 Overall Survival Overall Survival Overall Survival Overall Survival Overall Survival WHO 0, Age 70 WHO 1-2, Age Months since randomisation Months since randomisation WHO 0, Age 80 WHO 1-2, Age Months since randomisation RT, No Res Mass RT+CT, No Res Mass Months since randomisation RT, Res Mass 33 RT+CT, Res Mass
34 Presence of residual mass, extent of resection and tumour size are related Stage Logrank test p= 0.11 T2 T Months Size of tumour Logrank test p=0.001 <30mm >=30mm Unknown Months Extent of tumour resection Logrank test p= 0.04 Biopsy/Not resected Complete resection Incomplete resection Months Residual mass post resection Logrank test p=0.005 No Yes Months The presence of residual mass was highly correlated with extent of resection 96% complete resections without residual mass 66% incomplete resections with residual mass
35 TURBT and residual mass Residual mass = high stage High stage = poor prognosis Therefore does not follow that RT only for patients with no mass post TURBT as these patients will do badly with surgery Also does not follow that TURBT actually needed
36 Should we change the diagnostic pathway?
37 What if breast cancer specialists behaved like urologists? Breast cancer would be diagnosed by 6 random needle cores in each breast Initial treatment would use a hot wire to scrape the middle of the tumour out, leaving the invasive bits round the edge to grow for several weeks while staging proceeds
38 What is the point of TURBT? Diagnosis Staging Treatment Palliation of symptoms from bladder
39 Non-muscle invasive bladder cancer 80% of total TURBT Diagnosis Staging Treatment Palliation of symptoms from bladder
40 Invasive bladder cancer TURBT Diagnosis Staging Treatment Palliation of symptoms from bladder - incomplete No - delayed Possibly If we could diagnose and stage a different way, treatment would be faster
41 TURBT in MIBC 5% overt bladder perforation rate 50% occult bladder perforation Large increase in circulating tumour cells Around 20% of pts have T2-4NxM0 disease but half of these get metastasis Could TURBT be actually spreading the cancer?
42 MRI Superficial vs invasive Sensitivity T2 88% T2 + DWI 88% T2 + DCE 94% All 3 94% Specificity T2 74% T2 + DWI 100% T2 + DCE 86% All 3 100% TURBT pathological upstaging at cystectomy 40% Takeuchi M, Sasaki S, Ito M, Okada S, Takahashi S, Kawai T, Suzuki K, Oshima H, Hara M, Shibamoto Y. Urinary bladder cancer: diffusion-weighted MR imaging--accuracy for diagnosing T stage and estimating histologic grade. Radiology 2009;251:112-21
43 Ideal new pathway NMIBC Identify on imaging and biopsy/cytology Fast track to TURBT and subsequent therapy MIBC Stage with biopsy and MRI Fast track to definitive therapy TURBT only if urgently needed for symptoms e.g. intractable bleeding Problem: need to separate NMIBC from MIBC
44 BladderPath Trial Newly presented haematuria patients Randomise Standard care pathway Marker directed pathway Outcome measures: Stage 1: Feasibility, safety Stage 2: Time to primary treatment Stage 3: Failure free survival
45 BladderPath: Image Directed Redesign of Bladder Cancer Treatment Pathways Newly presented haematuria patients PIS given with Haematuria Clinic appointment letter Haematuria Clinic Informed consent 1 Flexible cystoscopy + cytology + imaging+ biopsy Diagnosis given Informed consent 2 Informed consent 1: Consenting all patients to biopsy (not standard) and collection of urine sample Patients without diagnosis of bladder cancer are excluded from study Informed consent 2: Consenting bladder cancer patients to the trial Randomisation A Probable NMIBC Pathway 1 (standard) TURBT Possible MIBC B C Probable NMIBC TURBT Pathway 2 Possible MIBC MRI D Feasibility test: H/D > 80% Intermediate test: Time from first consent to DT-F vs Time from first consent to DT-H E NMIBC MIBC F G NMIBC MIBC H Adjuvant treatment Chem o RT Surgery 1 st Definitive Treatment for F (DT-F) TURBT Chem RT Surgery 1 st o Definitive Treatment for H (DT-H)
46 BladderPath Feasibility stage 150 patients Intermediate stage event driven, at least 20 MIBC patients (approximately patients will need to be recruited overall). Final clinical stage event driven, (approximately 950 patients)
47 Patient 1 Presented with haematuria Large mass on flexible cystoscopy Biopsy G3TCC Proceeded direct to chemotherapy
48 Patient 2 Haematuria Flexible cystoscopy: 1.5 cm papillary tumour on left lateral wall Histology G2 TCC Stage T1N0M0
49 Patient 3 Transplant pt Solid mass at dome of bladder, partial TURBT done T4 on MRI with bowel infiltration Lower bowel defunctioned
50 Patient 3 (cont) Completed 55Gy/20 fractions + 5FU/MMC Post RT cystoscopy pathological CR
51 BladderPath feasibility early impressions MRI protocol works well to distinguish T1 from T2 and above Team happy to make treatment decisions without full TURBT Post therapy MRI can be used for treatment assessment The trial is ongoing
52 But radiotherapy leaves you a small poorly functioning bladder
53 Mean change from baseline Mean change from baseline Mean change from baseline Mean change from baseline B/L EOT 6m No. with data: N BLCS Change BLCS from in Change Baseline FACT BLCS from Score Change Baseline from Score domains Baseline Score BLCS (all Change patients) from Baseline Score Mean change from baseline Physical Well-Being Change from Baseline Score B/L EOT 6m No. with data: N * Mean change from baseline m B/L EOT 6m2 years12m B/L EOT3 6m years 2 years 12m 4 years 3 years 2 years 5 years 4 years 3 years No. with data: No. with data: 227 N N m 230 Mean change from baseline Mean 95% MeanCI Mean 95% CI 2 years Mean 3 years 4 years 5 years % CI Emotional Well-Being Change from Baseline Score * * * B/L EOT 6m No. with data: N * * * * Mean change from baseline Mean change from baseline Mean change from baseline Mean change from baseline 95% CI BLCS Change BLCS from Change Baseline BLCS from Score Change Baseline from Score Baseline Score Mean change from baseline m B/L EOT 6m2 years12m B/L EOT3 6m years 2 years 12m 4 years 3 years 2 years 5 years 4 years 3 years No. with data: No. with data: 227 N N Mean 95% MeanCI Mean 95% CI 95% CI Mean change from baseline 5 years 4 years B/L EOT 6m 5 years 12m B/L EOT 6m2 years12m B/L EOT3 6m years 2 years 12m No. with data: No. with data: No. with data: N N N B/L EOT 6m No. with data: N Social Well-Being Change from Baseline Score Mean change from baseline 12m 225 Mean change from baseline 2 years 162 Mean BLCS Change BLCS from Change Baseline from Score Base years 4 years 3 years 2 years 5 years 4 years 3 years Mean 95% MeanCI Mean 95% CI 9 4 years 5 years % CI Functional Well-Being Change from Baseline Score 5 years 4 years B/L EOT 6m 5 years 12m B/L EOT 6m2 years12m B/L EOT3 6m years 2 years 12m No. with data: No. with data: No. with data: N N N * BLCS Change BLCS from Change Baseline BLCS from Score Change Baseline from Score Base Mean change from baseline years 3 years 2 years 5 years 4 years 3 years Mean 95% MeanCI Mean 95% CI 9 B/L EOT 6m No. with data: N m years 167 Mean 3 years % CI 4 years years 104 B/L EOT 6m No. with data: N *Paired t-test, p m years 165 Mean 3 years % CI 4 years years 105
54 CAN WE SELECT PATIENTS FOR BLADDER PRESERVATION?
55 Patients unsuitable for surgery Elderly Severe cardiovascular or chest problems Obese Diabetes Patients reluctant or unable to cope with stoma etc
56 Patients unsuitable for (chemo)rt Poor bladder function Highly symptomatic bladders Extensive CIS Prior pelvic RT Inflammatory bowel disease Certain genetic disorders
57 Conclusions No convincing evidence surgery superior to primary bladder preservation with salvage surgery Synchronous chemo-radiation is safe and improves pelvic control and is complementary to neoadjuvant treatment Patient reported outcomes and long term follow up confirm the benefits reported in BC2001
Chemo-radiotherapy in muscle invasive bladder cancer. Dr Paula Wells St Bartholomew s Hospital London
Chemo-radiotherapy in muscle invasive bladder cancer Dr Paula Wells St Bartholomew s Hospital London Overview Evidence base for cystectomy vs bladder preservation Chemo-radiotherapy vs radiotherapy alone
More informationBladder Preservation Strategies for Muscle Invasive Bladder Cancer
Bladder Preservation Strategies for Muscle Invasive Bladder Cancer Jeff M. Michalski, MD, MBA, FACR, FASTRO The Carlos A. Perez Distinguished Professor of Radiation Oncology Department of Radiation Oncology
More informationSome Seminal Studies. Chemotherapy Alone is Inadequate. Bladder Cancer Role of Radiation in Bladder Sparing. Primary Radiation for Bladder Cancer
Bladder Cancer Role of Radiation in Bladder Sparing David C. Beyer M.D., FACR, FACRO, FASTRO Arizona Oncology Services Phoenix, Arizona Primary Radiation for Bladder Cancer No modern surgery / XRT randomized
More informationSeptember 10, Dear Dr. Clark,
September 10, 2015 Peter E. Clark, MD Chair, NCCN Bladder Cancer Guidelines (Version 2.2015) Associate Professor of Urologic Surgery Vanderbilt Ingram Cancer Center Nashville, TN 37232 Dear Dr. Clark,
More informationCHEMO-RADIOTHERAPY FOR BLADDER CANCER. Dr Darren Mitchell Consultant Clinical Oncologist Northern Ireland Cancer Centre
CHEMO-RADIOTHERAPY FOR BLADDER CANCER Dr Darren Mitchell Consultant Clinical Oncologist Northern Ireland Cancer Centre AIMS Muscle invasive disease Current Gold-Standard Rationale behind Chemo-Radiotherapy
More informationTrimodality Therapy for Muscle Invasive Bladder Cancer
Trimodality Therapy for Muscle Invasive Bladder Cancer Brita Danielson, MD, FRCPC Radiation Oncologist, Cross Cancer Institute Assistant Professor, Department of Oncology University of Alberta Edmonton,
More informationGuidelines for the Management of Bladder Cancer West Midlands Expert Advisory Group for Urological Cancer
Guidelines for the Management of Bladder Cancer West Midlands Expert Advisory Group for Urological Cancer West Midlands Clinical Networks and Clinical Senate Coversheet for Network Expert Advisory Group
More informationCollection of Recorded Radiotherapy Seminars
IAEA Human Health Campus Collection of Recorded Radiotherapy Seminars http://humanhealth.iaea.org Conservative Treatment of Invasive Bladder Cancer Luis Souhami, MD Professor Department of Radiation Oncology
More informationCochrane metaanalysis 5 year OS Intent to treat
RADICAL CYSTECTOMY IS THE ONLY EFFECTIVE TREATMENT FOR PATIENTS WITH OPERABLE MUSCLE INVASIVE BLADDER CANCER The Con position Scott Tyldesley Radiation Oncology, Vancouver Centre, BC Cancer Agency Cochrane
More informationBladder Cancer Guidelines
Bladder Cancer Guidelines Agreed by Urology CSG: October 2011 Review Date: September 2013 Bladder Cancer 1. Referral Guidelines The following patients should be considered as potentially having bladder
More information3/8/2014. Case Presentation. Primary Treatment of Anal Cancer. Anatomy. Overview. March 6, 2014
Case Presentation Primary Treatment of Anal Cancer 65 year old female presents with perianal pain, lower GI bleeding, and anemia with Hb of 7. On exam 6 cm mass protruding through the anus with bulky R
More informationNon Muscle Invasive Bladder Cancer. Primary and Recurrent TCC 4/10/2010. Two major consequences: Strategies: High-Risk NMI TCC
Intravesical Therapy 2010-When, with What, When to Stop Friday, April 9, 2010 Ralph de VereWhite, MD Director, UC Davis Cancer Center Associate Dean for Cancer Programs Professor, Department of Urolgoy
More information3.1 Investigations for Patients Presenting with Haematuria Table 1
3.1 Investigations for Patients Presenting with Haematuria Table 1 Patients at risk of bacterial endocarditis should be given antibiotic prophylaxis as per local guidelines. Patients with heart valve replacements
More informationUROTHELIAL CELL CANCER
UROTHELIAL CELL CANCER Indications and regimens for neoadjuvant systemic treatment Astrid A. M. van der Veldt, MD, PhD, medical oncologist Department of Medical Oncology Erasmus Medical Center Cancer Institute
More informationBladder Sparing Treatment of Muscle Invasive Bladder Cancer
Bladder Sparing Treatment of Muscle Invasive Bladder Cancer Pr Alexandre de la Taille CHU Mondor, Créteil INSERMU955Eq07 adelataille@hotmail.com High-Risk Invasive and Muscle-Invasive BCa Radical cystectomy
More informationMUSCLE - INVASIVE AND METASTATIC BLADDER CANCER
10 MUSCLE - INVASIVE AND METASTATIC BLADDER CANCER Recommendations from the EAU Working Party on Muscle Invasive and Metastatic Bladder Cancer G. Jakse (chairman), F. Algaba, S. Fossa, A. Stenzl, C. Sternberg
More informationDr. Tareq Salah Ahmed,MD,ESMO. Lecturer of clinical oncology, Assiut faculty of medicine ESMO accreditation certificate
Dr. Tareq Salah Ahmed,MD,ESMO Lecturer of clinical oncology, Assiut faculty of medicine ESMO accreditation certificate 1 st Assiut Urology department conference,marsa Alam 3 rd February 2015 Bladder cancer
More informationMini J.Elnaggar M.D. Radiation Oncology Ochsner Medical Center 9/23/2016. Background
Mini J.Elnaggar M.D. Radiation Oncology Ochsner Medical Center 9/23/2016 Background Mostly adenocarcinoma (scc possible, but treated like anal cancer) 39, 220 cases annually Primary treatment: surgery
More informationAdjuvant Therapies in Endometrial Cancer. Emma Hudson
Adjuvant Therapies in Endometrial Cancer Emma Hudson Endometrial Cancer Most common gynaecological cancer Incidence increasing in Western world 1-2% cancer deaths 75% patients postmenopausal 97% epithelial
More informationCase Conference. Craig Morgenthal Department of Surgery Long Island College Hospital
Case Conference Craig Morgenthal Department of Surgery Long Island College Hospital Neoadjuvant versus Adjuvant Radiation Therapy in Rectal Carcinoma Epidemiology American Cancer Society statistics for
More informationBladder Cancer in Primary Care. Dr Penny Kehagioglou Consultant Clinical Oncologist
Bladder Cancer in Primary Care Dr Penny Kehagioglou Consultant Clinical Oncologist Objectives Patient presentation in primary care Investigating bladder cancer Management of bladder cancer Differential
More informationWhen to Integrate Surgery for Metatstatic Urothelial Cancers
When to Integrate Surgery for Metatstatic Urothelial Cancers Wade J. Sexton, M.D. Senior Member and Professor Department of Genitourinary Oncology Moffitt Cancer Center Case Presentation #1 67 yo male
More informationRadical Cystectomy Often Too Late? Yes, But...
european urology 50 (2006) 1129 1138 available at www.sciencedirect.com journal homepage: www.europeanurology.com Editorial 50th Anniversary Radical Cystectomy Often Too Late? Yes, But... Urs E. Studer
More informationGuidelines for the Management of Bladder Cancer
Guidelines for the Management of Bladder Cancer Date Approved by Network Governance July 2012 Date for Review July 2015 Changes Between Version 3 and 4 Sections 5.2 and 8 updated Page 1 of 9 1. Scope of
More informationChemotherapy and Bladder Cancer. Blayne Welk UBC Urology Grand Rounds June 4, 2008
Chemotherapy and Bladder Cancer Blayne Welk UBC Urology Grand Rounds June 4, 2008 Outline Review of Incidence and Impact of bladder cancer Neoadjuvant chemotherapy Adjuvant chemotherapy Bladder preservation
More informationOptimal sequencing in treatment muscle invasive bladder cancer : oncologists. Phichai Chansriwong, MD Ramathibodi Hospital, Mahidol University
Optimal sequencing in treatment muscle invasive bladder cancer : oncologists Phichai Chansriwong, MD Ramathibodi Hospital, Mahidol University Slide 2 Presented By Andrea Apolo at 2018 Genitourinary Cancers
More informationreceive adjuvant chemotherapy
Women with high h risk early stage endometrial cancer should receive adjuvant chemotherapy Michael Friedlander The Prince of Wales Cancer Centre and Royal Hospital for Women The Prince of Wales Cancer
More informationAdvances in gastric cancer: How to approach localised disease?
Advances in gastric cancer: How to approach localised disease? Andrés Cervantes Professor of Medicine Classical approach to localised gastric cancer Surgical resection Pathology assessment and estimation
More informationRITE Thermochemotherapy in the treatment of BCG refractory NMIBC
RITE Thermochemotherapy in the treatment of BCG refractory NMIBC Ben Ayres Consultant Urological Surgeon St George s Hospital London 1 Financial and Other Disclosures Off-label use of drugs, devices, or
More informationNeoadjuvant vs. Adjuvant Chemotherapy for Muscle-Invasive Bladder Cancer
Neoadjuvant vs. Adjuvant Chemotherapy for Muscle-Invasive Bladder Cancer Andrew J. Stephenson, MD, FRCSC, FACS Director, Urologic Oncology Associate Professor of Surgery Glickman Urological and Kidney
More informationGUIDELINES ON NON-MUSCLE- INVASIVE BLADDER CANCER
GUIDELINES ON NON-MUSCLE- INVASIVE BLADDER CANCER (Limited text update December 21) M. Babjuk, W. Oosterlinck, R. Sylvester, E. Kaasinen, A. Böhle, J. Palou, M. Rouprêt Eur Urol 211 Apr;59(4):584-94 Introduction
More informationMedicinae Doctoris. One university. Many futures.
Medicinae Doctoris The Before and The After: Can chemotherapy revise the trajectory of gastric and esophageal cancers? Dr. David Dawe MD, FRCPC Medical Oncologist Assistant Professor Disclosures None All
More informationWhen radical prostatectomy is not enough: The evolving role of postoperative
When radical prostatectomy is not enough: The evolving role of postoperative radiation therapy Dr Tom Pickles Clinical Associate Professor, UBC. Chair, Provincial Genito-Urinary Tumour Group BC Cancer
More informationPreoperative adjuvant radiotherapy
Preoperative adjuvant radiotherapy Dr John Hay Radiation Oncology Program BC Cancer Agency Vancouver Cancer Centre The key question for the surgeon Do you think that this tumour can be resected with clear
More informationOld and New Radiation for Bladder and Upper Tract Cancers. Bridget Koontz Radiation Oncology Duke Cancer Institute
Old and New Radiation for Bladder and Upper Tract Cancers Bridget Koontz Radiation Oncology Duke Cancer Institute Disclosures Janssen funded clinical research BlueEarth Diagnostics advisory board member
More informationPROCARE FINAL FEEDBACK
1 PROCARE FINAL FEEDBACK General report 2006-2014 Version 2.1 08/12/2015 PROCARE indicators 2006-2014... 3 Demographic Data... 3 Diagnosis and staging... 4 Time to first treatment... 6 Neoadjuvant treatment...
More informationBladder Cancer. Clinical Case Conference
Bladder Cancer Clinical Case Conference Clinical Case 89 yo M with gross hematuria Labs: Chem: BUN/Cr increased 22/1.27 CBC: H/H 13/36, WBCs wnl UA: >50 RBCs, otherwise wnl UCx: No growth Cystoscopy at
More informationManagement options for high-risk, BCG-refractory NMIBC. Alan M. Nieder, M.D. Columbia University Division of Urology Mount Sinai Medical Center
Management options for high-risk, BCG-refractory NMIBC Alan M. Nieder, M.D. Columbia University Division of Urology Mount Sinai Medical Center Bladder Cancer in U.S. 4 th most common cancer in men 9 th
More informationChemotherapy Treatment Algorithms for Urology Cancer
Chemotherapy Treatment Algorithms for Urology Cancer Chemoradiation for bladder cancer; Chemotherapy algorithm for non TCC bladder cancer Squamous cell carcinoma; Chemotherapy Algorithm for Non Transitional
More informationGastroesophag Gastroesopha eal Junction Adenocarcinoma: What is the best adjuvant regimen? Michael G. G. H addock Haddock M.D.
Gastroesophageal Junction Adenocarcinoma: What is the best adjuvant regimen? Michael G. Haddock M.D. Mayo Clinic Rochester, MN Locally Advanced GE Junction ACA CT S CT or CT S CT/RT Proposition Chemoradiation
More informationNeodjuvant chemotherapy
Neodjuvant chemotherapy Dr Robert Huddart Senior Lecturer and Honorary Consultant in Clinical Oncology Royal Marsden Hospital and Institute of Cancer Research Why consider neo-adjuvant chemotherapy? Loco-regional
More informationSan Antonio Breast Cancer Symposium 2010 Highlights Radiotherapy
San Antonio Breast Cancer Symposium 2010 Highlights Radiotherapy Kathleen C. Horst, M.D. Assistant Professor Department of Radiation Oncology Stanford University The Optimal SEquencing of Adjuvant Chemotherapy
More informationMUSCLE-INVASIVE AND METASTATIC BLADDER CANCER
MUSCLE-INVASIVE AND METASTATIC BLADDER CANCER (Text update March 2008) A. Stenzl (chairman), N.C. Cowan, M. De Santis, G. Jakse, M. Kuczyk, A.S. Merseburger, M.J. Ribal, A. Sherif, J.A. Witjes Introduction
More informationAdjuvant Radiotherapy for completely resected NSCLC
Adjuvant Radiotherapy for completely resected NSCLC ESMO Preceptorship on lung Cancer Manchester February 2017 Cécile Le Péchoux Radiation Oncology Department IOT Institut d Oncologie Thoracique Local
More informationPre- Versus Post-operative Radiotherapy
Postoperative Radiation and Chemoradiation: Indications and Optimization of Practice Dislosures Clinical trial support from Genentech Inc. Sue S. Yom, MD, PhD Associate Professor UCSF Radiation Oncology
More informationVagina. 1. Introduction. 1.1 General Information and Aetiology
Vagina 1. Introduction 1.1 General Information and Aetiology The vagina is part of internal female reproductive system. It is an elastic, muscular tube that connects the outside of the body to the cervix.
More informationAlicia K. Morgans, MD Assistant Professor of Medicine Division of Hematology/Oncology Vanderbilt University Medical Center January 24, 2015
Alicia K. Morgans, MD Assistant Professor of Medicine Division of Hematology/Oncology Vanderbilt University Medical Center January 24, 2015 Overview Background Perioperative chemotherapy in MIBC Neoadjuvant
More informationPure non-bilharzial squamous cell carcinoma: An unusual form of carcinoma of the bladder
Safini et al. 31 case Series report peer Reviewed open OPEN ACCESS Pure non-bilharzial squamous cell carcinoma: An unusual form of carcinoma of the bladder Fatima Safini, Hassan Jouhadi, Meriem Elbachiri,
More informationRadiotherapy with or without Chemotherapy in Muscle-Invasive Bladder Cancer
T h e n e w e ngl a nd j o u r na l o f m e dic i n e original article with or without Chemotherapy in Muscle-Invasive Bladder Cancer Nicholas D. James, M.B., B.S., Ph.D., Syed A. Hussain, M.B., B.S.,
More informationTreatment of Invasive Bladder Cancer in the Elderly and Frail Pa9ent
Treatment of Invasive Bladder Cancer in the Elderly and Frail Pa9ent Jehonathan H Pinthus MD, Ph.D, FRCSC Associate Professor Department of Surgery/Urology McMaster University Life expectancy Current age
More informationNeoplasie uroteliali Posters & oral presentations
UPDATES and NEWS from the Genitourinary Cancers Symposium 3 Marzo 2017, Milano Neoplasie uroteliali Posters & oral presentations Cristina Masini Oncologia Medica IRCCS-Arcispedale S.Maria Nuova - Reggio
More informationIntravesical Therapy for Bladder Cancer
Intravesical Therapy for Bladder Cancer Alexandre R. Zlotta, MD, PhD, FRCSC Professor, Department of Surgery (Urology), University of Toronto Director, Uro-Oncology, Mount Sinai Hospital Director, Uro-Oncology
More informationRadiotherapy for Rectal Cancer. Kevin Palumbo Adelaide Radiotherapy Centre
Radiotherapy for Rectal Cancer Kevin Palumbo Adelaide Radiotherapy Centre Overview CRC are common (3 rd commonest cancer) rectal Ca approx 25-30% of all CRC. Presentation PR bleeding: beware attributing
More informationTristate Lung Meeting 2014 Pro-Con Debate: Surgery has no role in the management of certain subsets of N2 disease
Tristate Lung Meeting 2014 Pro-Con Debate: Surgery has no role in the management of certain subsets of N2 disease Jennifer E. Tseng, MD UFHealth Cancer Center-Orlando Health Sep 12, 2014 Background Approximately
More informationUrinary Bladder Cancer
Fellow GU Lecture Series, 2018 Urinary Bladder Cancer Asit Paul, MD, PhD 01/31/2018 Overview Non-muscle invasive bladder cancer Muscle invasive bladder cancer Bladder sparing chemo-radiation therapy T4b
More informationROBOTIC VS OPEN RADICAL CYSTECTOMY
ROBOTIC VS OPEN RADICAL CYSTECTOMY A REVIEW Colin Lundeen December 14, 2016 Objectives Review the history of radical cystectomy Critically analyze recent RCTs comparing open radical cystectomy (ORC) to
More informationTratamiento Multidisciplinar de Estadios Localmente Avanzados en Cáncer de Pulmón
Tratamiento Multidisciplinar de Estadios Localmente Avanzados en Cáncer de Pulmón Santiago Ponce Aix Servicio Oncología Médica Hospital Universitario 12 de Octubre Madrid Stage III: heterogenous disease
More informationUpdate on Neoadjuvant Chemotherapy (NACT) in Cervical Cancer
Update on Neoadjuvant Chemotherapy (NACT) in Cervical Cancer Nicoletta Colombo, MD University of Milan-Bicocca European Institute of Oncology Milan, Italy NACT in Cervical Cancer NACT Stage -IB2 -IIA>4cm
More informationBladder Preservation Protocols in the Treatment of Muscle-Invasive Bladder Cancer
Bladder-preserving therapy is a safe and effective alternative to cystectomy for carefully selected patients with bladder cancer. Michael Mahany. Trumpeter Swans on Byer s Lake. Photograph. Denali National
More informationReviewing Immunotherapy for Bladder Carcinoma In Situ
Reviewing Immunotherapy for Bladder Carcinoma In Situ Samir Bidnur Dept of Urologic Sciences, Grand Rounds March 1 st, 2017 Checkpoint Inhibition and Bladder Cancer, an evolving story with immunotherapy
More informationProstate Cancer Local or distant recurrence?
Prostate Cancer Local or distant recurrence? Diagnostic flowchart Vanessa Vilas Boas Urologist VFX Hospital FEBU PSA - only recurrence PSA recurrence: 27-53% of all patients undergoing treatment with curative
More informationAre we making progress? Marked reduction in operative morbidity and mortality
Are we making progress? Surgical Progress Marked reduction in operative morbidity and mortality Introduction of Minimal-Access approaches for complex esophageal cancer resections Significantly better functional
More informationLung Cancer Non-small Cell Local, Regional, Small Cell, Other Thoracic Cancers: The Question Isn t Can We, but Should We
Lung Cancer Non-small Cell Local, Regional, Small Cell, Other Thoracic Cancers: The Question Isn t Can We, but Should We Edward Garon, MD, MS Associate Professor Director- Thoracic Oncology Program David
More informationSelf-Assessment Module 2016 Annual Refresher Course
LS16031305 The Management of s With r. Lin Learning Objectives: 1. To understand the changing demographics of oropharynx cancer, and the impact of human papillomavirus on overall survival and the patterns
More informationAdjuvant Chemotherapy for Rectal Cancer: Are we making progress?
Adjuvant Chemotherapy for Rectal Cancer: Are we making progress? Hagen Kennecke, MD, MHA, FRCPC Division Of Medical Oncology British Columbia Cancer Agency October 25, 2008 Objectives Review milestones
More informationDe-Escalate Trial for the Head and neck NSSG. Dr Eleanor Aynsley Consultant Clinical Oncologist
De-Escalate Trial for the Head and neck NSSG Dr Eleanor Aynsley Consultant Clinical Oncologist 3 HPV+ H&N A distinct disease entity Leemans et al., Nature Reviews, 2011 4 Good news Improved response to
More informationCarcinoma del retto: Highlights
Carcinoma del retto: Highlights Stefano Cordio Struttura Complessa di Oncologia Medica ARNAS Garibaldi Catania Roma 17 Febbraio 2018 Disclosures Advisory Committee, research funding and speakers bureau
More informationHighlighting Clinical Trials Muscle Invasive Bladder Cancer
Highlighting Clinical Trials Muscle Invasive Bladder Cancer Part I: The Basics of MIBC Clinical Trials June 19, 2018 Presented by: Dr. Peter Black is a urologic oncologist at Vancouver General Hospital,
More informationEnterprise Interest None
Enterprise Interest None Cervical Cancer -Management of late stages ESP meeting Bilbao Spain 2018 Dr Mary McCormack PhD FRCR Consultant Clinical Oncologist University College Hospital London On behalf
More informationBreast cancer Can I still keep my breast?
Bladder Cancer Organ-Sparing Approaches SAMO Interdisciplinary Workshop on Urogenital Tumors September 15, 2012 Daniel R. Zwahlen, MD Radiation Oncology Breast cancer Can I still keep my breast? History
More informationCombined Modality Treatment of Anal Carcinoma
Combined Modality Treatment of Anal Carcinoma F. ROELOFSEN, a H. BARTELINK b a Bethesda Krankenhaus, Essen, Germany; b The Netherlands Cancer Institute/Antoni van Leeuwenhoek Ziekenhuis, Amsterdam, The
More informationSupplementary appendix
Supplementary appendix This appendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors. Supplement to: James RD, Glynne-Jones R, Meadows HM, et al.
More informationDebate: Adjuvant vs. Neoadjuvant Therapy for Urothelial Cancer
Debate: Adjuvant vs. Neoadjuvant Therapy for Urothelial Cancer Kala Sridhar, MD, MSc, FRCPC Medical Oncologist, Princess Margaret Hospital GU Medical Oncology Site Group Head Associate Professor, University
More informationAppendix 4 Urology Care Pathways
Appendix 4 Urology Care Pathways Cancer Care Pathways outline the steps and stages in the patient journey from referral through to diagnostics, staging, treatment, follow up, rehabilitation and if applicable
More informationCT PET SCANNING for GIT Malignancies A clinician s perspective
CT PET SCANNING for GIT Malignancies A clinician s perspective Damon Bizos Head, Surgical Gastroenterology Charlotte Maxeke Johannesburg Academic Hospital Case presentation 54 year old with recent onset
More informationINFORMATION AND SUPPORTIVE CARE NEEDS OF INDIVIDUALS WITH BLADDER CANCER
INFORMATION AND SUPPORTIVE CARE NEEDS OF INDIVIDUALS WITH BLADDER CANCER ROBIN MORASH APN, URO-ONCOLOGY JUNE 23, 2018 www.ottawahospital.on.ca Affiliated with Affilié à PRESENTATION CONTENT Overview of
More informationThe following slides are provided as presented by the author during the live educa7onal ac7vity and are intended for reference purposes only.
The following slides are provided as presented by the author during the live educa7onal ac7vity and are intended for reference purposes only. If you have any ques7ons, please contact Imedex via email at:
More informationCombining chemotherapy and radiotherapy of the chest
How to combine chemotherapy, targeted agents and radiotherapy in locally advanced NSCLC? Dirk De Ruysscher, MD, PhD Radiation Oncologist Professor of Radiation Oncology Leuven Cancer Institute Department
More informationOpen clinical uro-oncology trials in Canada
CLINICAL TRIALS Open clinical uro-oncology trials in Canada Eric Winquist, MD, Mary J. Mackenzie, MD, George Rodrigues, MD London Health Sciences Centre, London, Ontario, Canada ADRENOCORTICAL MALIGNANCIES
More informationLymph Node Positive Bladder Cancer Treated With Radical Cystectomy and Lymphadenectomy: Effect of the Level of Node Positivity
EUROPEAN UROLOGY 61 (2012) 1025 1030 available at www.sciencedirect.com journal homepage: www.europeanurology.com Bladder Cancer Lymph Node Positive Bladder Cancer Treated With Radical Cystectomy and Lymphadenectomy:
More informationIssues in the Management of High Risk Superficial Bladder Cancer
Issues in the Management of High Risk Superficial Bladder Cancer MICHAEL A.S. JEWETT DIVISION OF UROLOGY, DEPARTMENT OF SURGICAL ONCOLOGY, PRINCESS MARGARET HOSPITAL & THE UNIVERSITY OF TORONTO 1 Carcinoma
More informationUPDATE IN THE MANAGEMENT OF INVASIVE CERVICAL CANCER
UPDATE IN THE MANAGEMENT OF INVASIVE CERVICAL CANCER Susan Davidson, MD Professor Department of Obstetrics and Gynecology Division of Gynecologic Oncology University of Colorado- Denver Anatomy Review
More informationOpen clinical uro-oncology trials in Canada
Open clinical uro-oncology trials in Canada George Rodrigues, MD, Eric Winquist, MD, Mary J. Mackenzie, MD London Health Sciences Centre, London, Ontario, Canada ADRENOCORTICAL MALIGNANCIES CISPLATIN-BASED
More informationPoint/Counterpoint: Quality of Life Considerations for Patients with Muscle Invasive Bladder Cancer Pro Trimodality Therapy
Point/Counterpoint: Quality of Life Considerations for Patients with Muscle Invasive Bladder Cancer Pro Trimodality Therapy Kimberley S. Mak, MD, MPH Assistant Professor Boston Medical Center Boston University
More informationCase presentation. Paul De Leyn, MD, PhD Thoracic Surgery University Hospitals Leuven Belgium
Case presentation Paul De Leyn, MD, PhD Thoracic Surgery University Hospitals Leuven Belgium Perspectives in Lung Cancer Brussels 6-7 march 2009 LEUVEN LUNG CANCER GROUP Department of Thoracic Surgery
More informationThe Predictors of Local Recurrence after Radical Cystectomy in Patients with Invasive Bladder Cancer
The Predictors of Local Recurrence after Radical Cystectomy in Patients with Invasive Bladder Cancer Hiroki Ide, Eiji Kikuchi, Akira Miyajima, Ken Nakagawa, Takashi Ohigashi, Jun Nakashima and Mototsugu
More informationOpen clinical uro-oncology trials in Canada
Open clinical uro-oncology trials in Canada Eric Winquist, MD, Mary J. Mackenzie, MD, George Rodrigues, MD London Health Sciences Centre, London, Ontario, Canada ADRENOCORTICAL MALIGNANCIES CISPLATIN-BASED
More informationTransitional Cell Carcinoma of the Upper Ureter Metastatic to the Thoracic Spine Presenting as a Spinal Cord Compression
Case Study TheScientificWorldJOURNAL (2008) 8, 223 227 TSW Urology ISSN 1537-744X; DOI 10.1100/tsw.2008.43 Transitional Cell Carcinoma of the Upper Ureter Metastatic to the Thoracic Spine Presenting as
More informationEarly radical cystectomy in NMIBC Marko Babjuk
Early radical cystectomy in NMIBC Marko Babjuk Dept. of Urology, 2nd Faculty of Medicine, Hospital Motol, Praha, Czech Republic We Are The European Association of Urology We Are Urologists, residents,
More informationTreatment of oligometastatic NSCLC
Treatment of oligometastatic NSCLC Jarosław Kużdżał Department of Thoracic Surgery Jagiellonian University Collegium Medicum, John Paul II Hospital, Cracow New idea? 14 NSCLC patients with solitary extrathoracic
More information1. Introduction. 2. Methods. high-risk NMIBC in men with and without a prior history of RT for PC.
ISRN Urology Volume 2013, Article ID 405064, 5 pages http://dx.doi.org/10.1155/2013/405064 Research Article Radical Cystectomy after BCG Immunotherapy for High-Risk Nonmuscle-Invasive Bladder Cancer in
More informationProstate Cancer: 2010 Guidelines Update
Prostate Cancer: 2010 Guidelines Update James L. Mohler, MD Chair, NCCN Prostate Cancer Panel Associate Director for Translational Research, Professor and Chair, Department of Urology, Roswell Park Cancer
More informationCOLORECTAL CARCINOMA
QUICK REFERENCE FOR HEALTHCARE PROVIDERS MANAGEMENT OF COLORECTAL CARCINOMA Ministry of Health Malaysia Malaysian Society of Colorectal Surgeons Malaysian Society of Gastroenterology & Hepatology Malaysian
More informationRECTAL CANCER CLINICAL CASE PRESENTATION
RECTAL CANCER CLINICAL CASE PRESENTATION Francesco Sclafani Medical Oncologist, Clinical Research Fellow The Royal Marsden NHS Foundation Trust, London, UK esmo.org Disclosure I have nothing to declare
More informationPaul F. Schellhammer, M.D. Eastern Virginia Medical School Urology of Virginia Norfolk, Virginia
Paul F. Schellhammer, M.D. Eastern Virginia Medical School Urology of Virginia Norfolk, Virginia Virginia - Chesapeake Bay Landfall: Virginia Beach, April 29 th, 1607 PSA Failure after Radical Prostatectomy
More informationLocally advanced disease & challenges in management
Gynecologic Cancer InterGroup Cervix Cancer Research Network Cervix Cancer Education Symposium, February 2018 Locally advanced disease & challenges in management Carien Creutzberg Radiation Oncology, Leiden
More informationUpdate on Limited Small Cell Lung Cancer. Laurie E Gaspar MD, MBA Prof/Chair Radiation Oncology University of Colorado Denver
Update on Limited Small Cell Lung Cancer Laurie E Gaspar MD, MBA Prof/Chair Radiation Oncology University of Colorado Denver Objectives - Limited Radiation Dose Radiation Timing Radiation Volume PCI Neurotoxicity
More informationGynecologic Cancer InterGroup Cervix Cancer Research Network. Management of Cervical Cancer in Resource Limited Settings.
Management of Cervical Cancer in Resource Limited Settings Linus Chuang MD Conflict of Interests None Cervical cancer is the fourth most common malignancy in women worldwide 530,000 new cases per year
More informationESMO Preceptorship Programme, Colorectal Cancer, Vienna
State of the art multimodal treatment of anal cancer ESMO Preceptorship Programme, Colorectal Cancer, Vienna Rob Glynne-Jones Mount Vernon Centre for Cancer Treatment Disclosures: last 5 years Speaker:
More information